Drugs / XH-S004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06236841 | Jan 2024 → Jan 2025 | — | S-INFINITY Pharmaceuticals Co., Ltd | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-11 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million fosunpharma.com ↗ |
| 2025-07-17 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma’s Self-Developed New Drug XH-S004 for the Treatment of Chronic Obstructive Pulmonary Disease Enters Phase 1b Clinical Trial fosunpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XH-S004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06236841 ↗ |
| Route | Oral | “administered orally” NCT06236841 ↗ |